Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00301925
Recruitment Status : Active, not recruiting
First Posted : March 13, 2006
Last Update Posted : November 29, 2010
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating early stage breast cancer that has been removed by surgery.

PURPOSE: This randomized phase III trial is studying four different combination chemotherapy regimens to compare how well they work in treating patients with early stage breast cancer that has been removed by surgery.

Condition or disease Intervention/treatment Phase
Breast Cancer Biological: pegfilgrastim Drug: capecitabine Drug: cyclophosphamide Drug: epirubicin hydrochloride Drug: fluorouracil Drug: methotrexate Procedure: adjuvant therapy Phase 3

Detailed Description:



  • Compare the disease-free survival (DFS) of patients with completely resected early stage breast cancer receiving 1 of 2 different schedules of adjuvant chemotherapy comprising epirubicin, cyclophosphamide, methotrexate, and fluorouracil versus 1 of 2 different schedules of adjuvant chemotherapy comprising epirubicin and capecitabine.


  • Compare overall survival (OS) and distant disease-free survival (DFS).
  • Compare the tolerability (including serious adverse events [SAE], dose-intensity, and toxicity) of these regimens.
  • Determine the detailed toxicity of these regimens.
  • Determine the quality of life of a subset of these patients.

OUTLINE: This is a multi-center, randomized study. Patients are stratified according to participating center, nodal status (N0 vs N1-3 vs N≥ 4), age (≤ 50 years vs > 50 years), and estrogen receptor (ER) status (negative vs positive). Patients are randomized to 1 of 4 treatment arms.

  • Arm I: Patients receive epirubicin on day 1. Treatment repeats every 3 weeks for 4 courses. Patients then receive cyclophosphamide orally once daily on days 1-14 or IV on days 1 and 8 and methotrexate and fluorouracil on days 1 and 8. Treatment repeats every 28 days for 4 courses.
  • Arm II: Patients receive epirubicin on day 1 and pegfilgrastim on day 2. Treatment repeats every 2 weeks for 4 courses. Patients then receive cyclophosphamide, methotrexate and fluorouracil as in arm I.
  • Arm III: Patients receive epirubicin as in arm I. Patients then receive oral capecitabine twice daily on days 1-14. Treatment with capecitabine repeats every 3 weeks for 4 courses.
  • Arm IV: Patients receive epirubicin and pegfilgrastim as in arm II. Patients then receive capecitabine as in arm III.

In all arms, treatment continues in the absence of unacceptable toxicity.

Beginning 3-6 months later, all patients may undergo radiotherapy at the discretion of the principal investigator. Patients with ER- and/or progesterone receptor-positive disease then receive tamoxifen citrate or an aromatase inhibitor for up to 5 years.

Quality of life is assessed in a cohort of 1,000 patients in week 6, week 8 or 12, and week 20 or 24 during treatment and then at 12 and 24 months after randomization.

After completion of study therapy, patients are followed every 6 months for 2 years and then annually for at least 10 years.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.

PROJECTED ACCRUAL: A total of 4,400 patients will be accrued for this study.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 4400 participants
Allocation: Randomized
Primary Purpose: Treatment
Official Title: Trial of Accelerated Adjuvant Chemotherapy With Capecitabine in Early Breast Cancer (TACT2)
Study Start Date : December 2005
Estimated Primary Completion Date : September 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Primary Outcome Measures :
  1. Disease-free survival (DFS) at 5 years

Secondary Outcome Measures :
  1. Overall survival at 5 years
  2. Distant DFS at 5 years
  3. Tolerability (including serious adverse events, dose-intensity, and toxicity)
  4. Detailed toxicity
  5. Quality of life

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histological diagnosis of invasive breast carcinoma

    • Cytological proof of malignancy alone is not sufficient
    • Early stage disease (T0-3, N0-2, M0) without clinical suspicion or evidence of distant metastases on routine staging
    • No locally advanced breast cancer (T4 and/or N3 disease)
  • Completely resected disease by breast-conserving surgery with axillary node clearance or modified radical mastectomy within the past 4-8 weeks

    • Negative surgical margins required, unless either of the following are true:

      • Deep surgical margins after full thickness resection
      • Noninvasive cancer at surgical margins for which a mastectomy is planned after completion of study chemotherapy
    • No contraindication for or refusal of postoperative radiotherapy in patients who underwent prior breast-conserving surgery
  • Definite indication for adjuvant chemotherapy
  • No prior or current invasive breast cancer or bilateral breast cancer

    • Prior surgically-treated ductal carcinoma in situ or lobular carcinoma in situ allowed
  • Hormone receptor status:

    • Estrogen receptor- and/or progesterone receptor-positive or -negative tumor


  • Sex: male or female
  • Menopausal status: premenopausal or postmenopausal
  • No previous malignancy except basal cell carcinoma, carcinoma in situ of the cervix, or any cancer from which the patient has been disease-free for 10 years and for which treatment consisted solely of resection
  • ECOG status 0 or 1
  • Hemoglobin > 9 g/dL
  • WBC > 3,000/mm³
  • Platelet count > 10,000/mm³
  • Bilirubin normal (unless due to known Gilbert's disease)
  • AST and ALT ≤ 1.5 times upper limit of normal (ULN)
  • Albumin normal
  • Creatinine ≤ 1.5 times ULN
  • Creatinine clearance > 50 mL/min
  • No active, uncontrolled infection
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No concurrent medical, psychiatric, or geographic problems that might prevent completion of treatment or follow-up
  • Available for a minimum of 5 years' follow-up
  • No known serious viral infection such as active hepatitis B, hepatitis C, or HIV
  • No significant cardiac disease, such as impaired left ventricular function or active angina requiring regular anti-anginal medication and/or resulting in restricted physical activity
  • No history of significant renal impairment or disease


  • No simultaneous participation in the active intervention phase of another treatment trial
  • Not being approached or recruited for another trial within 2 months of study entry
  • No previous chemotherapy, hormonal therapy or radiotherapy for the treatment of pre-invasive or invasive cancer except for either of the following:

    • Previous radiotherapy for basal cell carcinoma
    • Previous preoperative endocrine therapy, provided there was no evidence of progression during this therapy, it lasted for less than 6 weeks in duration, and it was stopped at least one month prior to trial entry
  • Concurrent luteinizing hormone-releasing hormone analog therapy allowed for premenopausal patients
  • More than 4 weeks since prior hormone replacement therapy (HRT) or pre-operative endocrine therapy
  • No prior breast conserving surgery if there is a contradiction for or refusal of postoperative radiotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00301925

  Show 152 Study Locations
Sponsors and Collaborators
Institute of Cancer Research, United Kingdom
Study Chair: David Cameron, MD National Cancer Research Network

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00301925     History of Changes
Other Study ID Numbers: CDR0000463447
First Posted: March 13, 2006    Key Record Dates
Last Update Posted: November 29, 2010
Last Verified: July 2009

Keywords provided by National Cancer Institute (NCI):
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer
male breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors